1nhaler announced that it has closed a £2.2 million funding round led by Archangels, with the proceeds intended to support preparations for a clinical trial of its disposable, single-dose 1nhaler Salbutamol DPI with a goal of submitting a regulatory filing by the end of 2027. Some of the funds will also support a Harro Höfliger study in preparation for potential commercial production of the cardboard inhaler.
In 2023, the company announced that it had raised £2 million for development of the device, followed by a £1.5 million funding in 2025. 1nhaler announced a number of board appointments in 2024; according to the company web site, Gordon Muirhead has since replaced Jane Gaddum as Chair.
1nhaler CEO Lisa McMyn commented, “This investment takes us to one of the most important milestones in our journey, taking our own lead product into the clinic. The continued backing of Archangels, Scottish Enterprise, and BBB Investments reflects the technical and commercial progress we have made over the past year.”
Archangels Director and Head of New Investments Sarah Hardy said, “Having backed 1nhaler since 2023, we see this latest round as a reflection of our confidence in the team and its novel inhaler device that has the potential to disrupt the global market for inhaled medicines. We are particularly excited by the commercial traction and interest from potential partners across a broader range of drugs than we initially anticipated, highlighting the platform’s versatility and market potential. Taking this product into a clinical study is a significant milestone towards demonstrating its performance in patients. Working alongside our co-investors, we look forward to supporting 1nhaler through its next stage of growth as it builds towards regulatory approval and commercialization.”
Read the 1inhaler press release
